484 related articles for article (PubMed ID: 23631635)
1. Reduced α-synuclein levels in cerebrospinal fluid in Parkinson's disease are unrelated to clinical and imaging measures of disease severity.
van Dijk KD; Bidinosti M; Weiss A; Raijmakers P; Berendse HW; van de Berg WD
Eur J Neurol; 2014 Mar; 21(3):388-94. PubMed ID: 23631635
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal analyses of cerebrospinal fluid α-Synuclein in prodromal and early Parkinson's disease.
Mollenhauer B; Caspell-Garcia CJ; Coffey CS; Taylor P; Singleton A; Shaw LM; Trojanowski JQ; Frasier M; Simuni T; Iranzo A; Oertel W; Siderowf A; Weintraub D; Seibyl J; Toga AW; Tanner CM; Kieburtz K; Chahine LM; Marek K; Galasko D;
Mov Disord; 2019 Sep; 34(9):1354-1364. PubMed ID: 31361367
[TBL] [Abstract][Full Text] [Related]
3. Tau/α-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study.
Delgado-Alvarado M; Gago B; Gorostidi A; Jiménez-Urbieta H; Dacosta-Aguayo R; Navalpotro-Gómez I; Ruiz-Martínez J; Bergareche A; Martí-Massó JF; Martínez-Lage P; Izagirre A; Rodríguez-Oroz MC
Mov Disord; 2017 Jul; 32(7):1066-1073. PubMed ID: 28548309
[TBL] [Abstract][Full Text] [Related]
4. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
[TBL] [Abstract][Full Text] [Related]
5. Relationship between cerebrospinal fluid biomarkers and structural brain network properties in Parkinson's disease.
Abbasi N; Mohajer B; Abbasi S; Hasanabadi P; Abdolalizadeh A; Rajimehr R
Mov Disord; 2018 Mar; 33(3):431-439. PubMed ID: 29436735
[TBL] [Abstract][Full Text] [Related]
6. Correlates of cerebrospinal fluid levels of oligomeric- and total-α-synuclein in premotor, motor and dementia stages of Parkinson's disease.
Compta Y; Valente T; Saura J; Segura B; Iranzo Á; Serradell M; Junqué C; Tolosa E; Valldeoriola F; Muñoz E; Santamaria J; Cámara A; Fernández M; Fortea J; Buongiorno M; Molinuevo JL; Bargalló N; Martí MJ
J Neurol; 2015 Feb; 262(2):294-306. PubMed ID: 25380583
[TBL] [Abstract][Full Text] [Related]
7. Phosphorylated α-synuclein in Parkinson's disease: correlation depends on disease severity.
Stewart T; Sossi V; Aasly JO; Wszolek ZK; Uitti RJ; Hasegawa K; Yokoyama T; Zabetian CP; Leverenz JB; Stoessl AJ; Wang Y; Ginghina C; Liu C; Cain KC; Auinger P; Kang UJ; Jensen PH; Shi M; Zhang J
Acta Neuropathol Commun; 2015 Jan; 3():7. PubMed ID: 25637461
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis.
Gao L; Tang H; Nie K; Wang L; Zhao J; Gan R; Huang J; Zhu R; Feng S; Duan Z; Zhang Y; Wang L
Int J Neurosci; 2015; 125(9):645-54. PubMed ID: 25202803
[TBL] [Abstract][Full Text] [Related]
9. Extrastriatal SPECT-DAT uptake correlates with clinical and biological features of de novo Parkinson's disease.
Sampedro F; Marín-Lahoz J; Martínez-Horta S; Camacho V; Lopez-Mora DA; Pagonabarraga J; Kulisevsky J
Neurobiol Aging; 2021 Jan; 97():120-128. PubMed ID: 33212336
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal striatal dopamine transporter binding and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau, and phosphorylated tau in Parkinson's disease.
Nabizadeh F; Pirahesh K; Ramezannezhad E
Neurol Sci; 2023 Feb; 44(2):573-585. PubMed ID: 36227385
[TBL] [Abstract][Full Text] [Related]
11. Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects.
Mollenhauer B; Trautmann E; Taylor P; Manninger P; Sixel-Döring F; Ebentheuer J; Trenkwalder C; Schlossmacher MG
Neurosci Lett; 2013 Jan; 532():44-8. PubMed ID: 23149132
[TBL] [Abstract][Full Text] [Related]
12. Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: evidence from a meta-analysis.
Sako W; Murakami N; Izumi Y; Kaji R
Mov Disord; 2014 Nov; 29(13):1599-605. PubMed ID: 25258345
[TBL] [Abstract][Full Text] [Related]
13. Immunochemical Detection of α-Synuclein Autoantibodies in Parkinson's Disease: Correlation between Plasma and Cerebrospinal Fluid Levels.
Horvath I; Iashchishyn IA; Forsgren L; Morozova-Roche LA
ACS Chem Neurosci; 2017 Jun; 8(6):1170-1176. PubMed ID: 28263550
[TBL] [Abstract][Full Text] [Related]
14. Evolution of cerebrospinal fluid total α-synuclein in Parkinson's disease.
Førland MG; Öhrfelt A; Dalen I; Tysnes OB; Blennow K; Zetterberg H; Pedersen KF; Alves G; Lange J
Parkinsonism Relat Disord; 2018 Apr; 49():4-8. PubMed ID: 29409704
[TBL] [Abstract][Full Text] [Related]
15. REM behavior disorder predicts motor progression and cognitive decline in Parkinson disease.
Pagano G; De Micco R; Yousaf T; Wilson H; Chandra A; Politis M
Neurology; 2018 Sep; 91(10):e894-e905. PubMed ID: 30089615
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers.
Vilas D; Shaw LM; Taylor P; Berg D; Brockmann K; Aasly J; Marras C; Pont-Sunyer C; Ríos J; Marek K; Tolosa E
Mov Disord; 2016 Jun; 31(6):906-14. PubMed ID: 27041685
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias.
Parnetti L; Chiasserini D; Bellomo G; Giannandrea D; De Carlo C; Qureshi MM; Ardah MT; Varghese S; Bonanni L; Borroni B; Tambasco N; Eusebi P; Rossi A; Onofrj M; Padovani A; Calabresi P; El-Agnaf O
Mov Disord; 2011 Jul; 26(8):1428-35. PubMed ID: 21469206
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of cerebrospinal fluid α-synuclein seeding aggregation assays for diagnosis of Parkinson's disease.
Kang UJ; Boehme AK; Fairfoul G; Shahnawaz M; Ma TC; Hutten SJ; Green A; Soto C
Mov Disord; 2019 Apr; 34(4):536-544. PubMed ID: 30840785
[TBL] [Abstract][Full Text] [Related]
19. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease.
Tokuda T; Salem SA; Allsop D; Mizuno T; Nakagawa M; Qureshi MM; Locascio JJ; Schlossmacher MG; El-Agnaf OM
Biochem Biophys Res Commun; 2006 Oct; 349(1):162-6. PubMed ID: 16930553
[TBL] [Abstract][Full Text] [Related]
20. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
Tissingh G; Booij J; Bergmans P; Winogrodzka A; Janssen AG; van Royen EA; Stoof JC; Wolters EC
J Nucl Med; 1998 Jul; 39(7):1143-8. PubMed ID: 9669384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
